Alnylam Pharmaceuticals Inc.
Alnylam Announces Convertible Senior Notes Offering
Summary
Alnylam Pharmaceuticals, Inc. announced the commencement of its proposed offering of $500 million convertible senior notes due 2028 to qualified institutional buyers under Rule 144A. The notes, which are senior, unsecured obligations, will accrue interest payable semi-annually and mature on September 15, 2028. Noteholders have the right to convert their notes in certain circumstances and during specified periods. The offering of the notes is subject to market conditions and there can be no assurance as to when the offering may be completed, or as to the actual size or terms of the offering. Alnylam intends to use a portion of the net proceeds from the offering to pay the cost of capped call transactions and to repurchase a portion of its existing 1.00% convertible senior notes due 2027.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement